Do you want to read an article? Please log in or register.
Clinical Factors Associated with Suspicious (18)F-DCFPyL PSMA PET Activity in Patients Initially Managed with Radical Prostatectomy including PSA
Genitourinary Cancer
Related content
Genitourinary Cancer
Multiparametric MRI and (18)F-PSMA-1007 PET/CT for the Detection of Clinically Significant Prostate Cancer
Radiology
Privé BM, Israël B, Janssen MJR, van der Leest MMG, de Rooij M, van Ipenburg JA, Jonker M, Peters SMB, de Groot M, Zámecnik P, Hoepping A, Bomers JG, Gotthardt M, Sedelaar JPM, Barentsz JO, van Oort IM, Nagarajah J
doi: 10.1148/radiol.231879
Genitourinary Cancer
Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [(177)Lu]Lu-PSMA-617 in the Phase 3 VISION Trial
Eur Urol
Armstrong AJ, Sartor O, de Bono J, Chi K, Fizazi K, Krause BJ, Herrmann K, Rahbar K, Tagawa ST, Saad F, Beer TM, Wu J, Mirante O, Morris MJ
doi: 10.1016/j.eururo.2024.08.021
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [(18)F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Oncol
Vera P, Thureau S, Le Tinier F, Chaumet-Riffaud P, Hapdey S, Kolesnikov-Gauthier H, Martin E, Berriolo-Riedinger A, Pourel N, Broglia JM, Boissellier P, Guillemard S, Salem N, Brenot-Rossi I, Le Péchoux C, Berthold C, Giroux-Leprieur E, Moreau D, Guillerm S, Benali K, Tessonnier L, Audigier-Valette C, Lerouge D, Quak E, Massabeau C, Courbon F, Moisson P, Larrouy A, Modzelewski R, Gouel P, Ghazzar N, Langlais A, Amour E, Zalcman G, Giraud P
doi: 10.1016/S1470-2045(24)00320-6
ESMO 2024
Genitourinary Cancer
223Ra followed by 177Lu-PSMA was clinically feasible in heavily pretreated patients with mCRPC in clinical practice
Genitourinary Cancer
Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study
Lancet Oncol
Karpinski MJ, Hüsing J, Claassen K, Möller L, Kajüter H, Oesterling F, Grünwald V, Umutlu L, Kleesiek J, Telli T, Merkel-Jens A, Hüsing A, Kesch C, Herrmann K, Eiber M, Hoberück S, Meyer PT, Kind F, Rahbar K, Schäfers M, Stang A, Hadaschik BA, Fendler WP
doi: 10.1016/S1470-2045(24)00326-7
COMMENTED
Genitourinary CancerNuclear Medicine
Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial)
★ 2
Recommended and commented by
Prof. Dr Ken Herrmann, Faculty Member
Radiology
Kuo PH, Morris MJ, Hesterman J, Kendi AT, Rahbar K, Wei XX, Fang B, Adra N, Garje R, Michalski JM, Chi K, de Bono J, Fizazi K, Krause B, Sartor O, Tagawa ST, Ghebremariam S, Brackman M, Wong CC, Catafau AM, Benson T, Armstrong AJ, Herrmann K
doi: 10.1148/radiol.233460
Lung, Respiratory and Thoracic Cancer
Body Weight Gain Associated With Alectinib in Patients With ALK+ Non-Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical Trials
J Clin Oncol
Sikkema BJ, Baart SJ, Paats MS, Smit EF, Schols AMWJ, Mathijssen RHJ, van Rossum EFC, Dingemans AC
doi: 10.1200/JCO-24-01579
COMMENTED
Genitourinary CancerNuclear Medicine
Efficacy and safety of rechallenge [177Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study)
★ 1
Recommended and commented by
Prof. Dr Ken Herrmann, Faculty Member
Eur J Nucl Med Mol Imaging
Rosar F, Schuler J, Burgard C, Blickle A, Bartholomä M, Maus S, Petto S, Khreish F, Schaefer A, Ezziddin S
doi: 10.1007/s00259-024-06825-4
ASH 2024
Lymphoma